Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

528
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
528
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

261
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
261
Neural Regulation01:37

Neural Regulation

39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

465
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
465
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K
Postsynaptic Potential (PSP)01:32

Postsynaptic Potential (PSP)

2.5K
Postsynaptic potential (PSP) refers to a change in the electrical potential of a neuron when neurotransmitters released by presynaptic neurons bind to postsynaptic receptors. This potential can either be excitatory, leading to depolarization and ultimately action potential generation, or inhibitory, leading to hyperpolarization and suppression of the postsynaptic neuron.
There are two types of receptors: ionotropic and metabotropic.
The ionotropic receptor is the membrane protein that has an...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets.

Experimental neurology·2026
Same author

Association of a five-metabolite and early-symptom profile with Parkinson's disease and its clinical progression.

Scientific reports·2026
Same author

Giant Sellar Meningocele: Intact Pituitary Function and New-onset Arginine Vasopressin Deficiency After Surgery.

JCEM case reports·2025
Same author

Genetic changes in regulatory immune cells induced by pramipexole and rotigotine: implications for the treatment of Parkinson's disease.

Inflammopharmacology·2025
Same author

Advanced clinical stage Parkinson's disease is linked to proinflammatory and regulatory blood cell populations.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2025
Same author

Neurodegeneration models in Parkinson's disease: cellular and molecular paths to neuron death.

Behavioral and brain functions : BBF·2025

Related Experiment Video

Updated: Jun 25, 2025

Technique for Intranasal Administration of α-Synuclein Aggregates
04:49

Technique for Intranasal Administration of α-Synuclein Aggregates

Published on: November 8, 2024

441

Progressive Supranuclear Palsy Syndrome: An Overview.

Eduardo Ichikawa-Escamilla1, Rodrigo A Velasco-Martínez1, Laura Adalid-Peralta1

  • 1Laboratorio de Reprogramación Celular del Instituto de Fisiología Celular, UNAM, en el Instituto Nacional de Neurología y Neurocirugía "Manuel Velasco Suarez", Mexico City 14269, Mexico.

IBRO Neuroscience Reports
|May 27, 2024
PubMed
Summary

This review explores neuroinflammation and peripheral inflammation in progressive supranuclear palsy syndrome (PSP-S). Understanding these inflammatory processes is crucial for developing new biomarkers and treatments for PSP-S.

Keywords:
NeurodegenerationNeuroinflammationProgressive supranuclear palsy

More Related Videos

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

10.6K
Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo
09:44

Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo

Published on: June 2, 2019

21.4K

Related Experiment Videos

Last Updated: Jun 25, 2025

Technique for Intranasal Administration of α-Synuclein Aggregates
04:49

Technique for Intranasal Administration of α-Synuclein Aggregates

Published on: November 8, 2024

441
Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

10.6K
Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo
09:44

Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo

Published on: June 2, 2019

21.4K

Area of Science:

  • Neuroscience
  • Immunology
  • Neurology

Background:

  • Progressive supranuclear palsy syndrome (PSP-S) is a neurodegenerative disease within the parkinsonian disorders group.
  • While clinically similar to Parkinson's disease, PSP-S differs in pathophysiology.
  • Corticobasal syndrome (CBS) shares tau-related pathophysiology and clinical features with PSP-S.

Purpose of the Study:

  • To review current knowledge on neuroinflammation and peripheral inflammation in PSP-S.
  • To highlight the role of microglial cells in PSP-S pathogenesis.
  • To identify gaps in research regarding inflammatory biomarkers for PSP-S.

Main Methods:

  • Literature review focusing on neuroimaging and immunological studies.
  • Analysis of studies investigating inflammatory biomarkers in PSP-S.
  • Synthesis of information on the role of inflammation in PSP-S development and progression.

Main Results:

  • Neuroinflammation, particularly involving microglial cells, is implicated in PSP-S.
  • Studies have explored inflammatory biomarkers, but significant advances are lacking.
  • Peripheral inflammation's role in PSP-S requires further investigation.

Conclusions:

  • Inflammation is a key area for understanding PSP-S pathophysiology.
  • Further research into inflammatory biomarkers is needed for diagnostic and therapeutic advancements.
  • Targeting inflammatory pathways may offer future therapeutic strategies for PSP-S.